Ossiam Buys 2,236 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Ossiam lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 22.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,095 shares of the medical research company's stock after acquiring an additional 2,236 shares during the period. Ossiam's holdings in Thermo Fisher Scientific were worth $6,292,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TMO. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $28,000. FPC Investment Advisory Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $28,000. Missouri Trust & Investment Co purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Pillar Financial Advisors LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Endeavor Private Wealth Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $30,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Down 1.2 %

Shares of NYSE:TMO traded down $5.07 during trading on Thursday, hitting $426.57. The stock had a trading volume of 3,661,206 shares, compared to its average volume of 1,737,439. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12 month low of $409.85 and a 12 month high of $627.88. The company has a market capitalization of $161.03 billion, a PE ratio of 25.81, a PEG ratio of 2.99 and a beta of 0.86. The firm's fifty day moving average is $491.37 and its 200 day moving average is $530.03.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a $0.43 dividend. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific's payout ratio is currently 10.41%.

Analysts Set New Price Targets

TMO has been the topic of a number of research analyst reports. UBS Group reduced their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday. Finally, Royal Bank of Canada cut their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $618.68.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares of the company's stock, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock valued at $13,106,062 in the last 90 days. Corporate insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.